Status: Not yet recruiting
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The primary goal is to assess treatment-related toxicity, while secondary objectives include progression-free survival, overall survival, and quality of life. The study will enroll 32 patients.
Participants needed: 32
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Houda BahigUpdated: Oct 2, 2024Locations: 1
Eligibility criteria
Participants must be ≥ 18 years old [+9]
Pregnant or breastfeeding individuals are excluded. [+4]